Erasca, Inc. (ERAS)

Over the past six months, Erasca's stock has experienced significant volatility and positive performance, increasing by 338.73%. Several analyst upgrades and price target increases occurred, with firms like HC Wainwright & Co., Piper Sandler, Mizuho, Guggenheim, and Stifel initiating or raising their ratings and price targets. Conversely, B of A Securities downgraded Erasca. General Counsel Ebun Garner sold 120,000 shares of the company's stock. Erasca announced promising early clinical data for ERAS-0015 and outlined 2026-2027 milestones. A U.S. Composition of Matter Patent was issued for ERAS-0015. IND clearance was granted for ERAS-0015 in May 2025, and for ERAS-4001 in June 2025. As of September 30, 2025, Erasca reported cash, cash equivalents, and marketable securities of $362.4 million, projected to fund operations into the second half of 2028.

As a clinical-stage biopharmaceutical company, Erasca, Inc. does not have commercialized products or services subject to traditional demand seasonality. Its demand is primarily related to investor interest and the need for capital to fund its research and development pipeline, which are not typically seasonal. The company's financial health and ability to fund operations are driven by clinical trial progress, regulatory milestones, and successful financing rounds.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The company aims to erase cancer by targeting signaling pathways in cancer cells, particularly the RAS/MAPK pathway. Erasca's product pipeline includes small molecules, large molecules, and protein degraders designed to inhibit or degrade critical signaling nodes of the RAS/MAPK pathway. Key product candidates include Naporafenib, ERAS-007, ERAS-601, ERAS-0015, and ERAS-4001.

Erasca, Inc. is headquartered in San Diego, California. The company has secured U.S. clinical sites for its trials and holds global rights to its product candidates outside of Greater China.

Erasca's brand reputation is shaped by its commitment to scientific innovation and progress in developing therapies for RAS/MAPK pathway-driven cancers. The company has cultivated a reputation for building one of the deepest RAS/MAPK pathway-focused pipelines in the biotechnology sector. Promising clinical data for ERAS-0015, regulatory milestones such as IND clearance for ERAS-0015 and ERAS-4001, and Naporafenib receiving Fast Track Designation from the FDA have positively impacted its reputation. Strategic presentations at healthcare conferences and the promotion of Robert Shoemaker to Chief Scientific Officer have also contributed. The extended cash runway into the second half of 2028 demonstrates financial health.

Erasca, Inc.'s ownership is primarily institutional, with approximately 65.43% to 73.56% held by institutional investors, 12.38% by insiders, and 8.13% to 14.06% by public companies and individual investors. Major institutional owners include Frazier Life Sciences Management, L.P., T. Rowe Price Investment Management, Inc., VR Adviser, LLC, Logos Global Management LP, BlackRock, Inc., Suvretta Capital Management, Llc, Paradigm Biocapital Advisors LP, Vanguard Group Inc, Arch Venture Corp, Vivo Capital, LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Goldman Sachs Group Inc., and State Street Global Advisors, Inc. Jonathan E. Lim, M.D., is the largest individual shareholder.